We serve Chemical Name:Isonicotinamide CAS:1453-82-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Isonicotinamide
CAS.NO:1453-82-3
Synonyms:4-Pyridine carboxamide;MFCD00006432;4-pyridinecarboximidic acid;4-Pyridinecarboxamide;EINECS 215-926-2;4-(HYDROXYIMINOMETHYL)PYRIDINE;Isonicotinamide;Pyridine-4-carboximidic acid;pyridine-4-carboxamide
Molecular Formula:C6H6N2O
Molecular Weight:122.125
HS Code:29333999
Physical and Chemical Properties:
Melting point:155-157 °C(lit.)
Boiling point:334.4±15.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.570
PSA:55.98000
Exact Mass:122.048012
LogP:-0.28
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 4-Pyridine carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,pyridine-4-carboxamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Pyridine carboxamide Use and application,4-Pyridinecarboxamide technical grade,usp/ep/jp grade.
Related News: In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. Isonicotinamide manufacturer Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. Isonicotinamide supplier Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. Isonicotinamide vendor The United Kingdom, for instance, is now warning against all but essential travel to mainland China, and is advising against all travel to Hubei province, where the outbreak was first reported. Isonicotinamide factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.
